The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Prostate cancer often earns the label “silent killer” because it can develop and progress for years without producing noticeable symptoms. Understanding this timeline becomes crucial for men seeking ...

As a physician, researcher, and biotech leader with personal experience of prostate cancer in my family, I’ve long advocated for putting patients first in our quest for medical innovation. Today, I ...

Researchers have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of ...

The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has emerged over the past two decades.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results ...

Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...